Skip to main content
Top

2024 | OriginalPaper | Hoofdstuk

17. Infecties van de lever

Auteurs : A. A. van der Eijk, F. Nevens, R. A. de Man

Gepubliceerd in: Leerboek microbiologie en infectieziekten

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

De lever, het grootste orgaan in de buikholte, speelt een centrale rol in de stofwisseling van glucose, aminozuren en vetten. Het orgaan is daarnaast verantwoordelijk voor de productie van albumine en stollingsfactoren. Afbraak en uitscheiding van lichaamseigen stoffen als bilirubine, ammoniak en hormonen en het ontgiften van lichaamsvreemde stoffen geschieden grotendeels in de lever. Ontsteking van de lever (hepatitis) heeft verschillende oorzaken: toxische beschadiging (alcohol, drugs, geneesmiddelen), stofwisselingsziekten (ijzer, koper, enzym defecten), auto-immuniteit, vetstapeling en infectie. Verschillende bacteriën, protozoën, schimmels en wormen zijn in staat de lever te infecteren, maar virale hepatitis is veruit de belangrijkste vorm van infectieuze hepatitis. Infectie met cytomegalovirus of Epstein-Barr-virus (ziekte van Pfeiffer) gaat soms gepaard met hepatitis. In dit hoofdstuk worden behalve de hepatitisvirussen A t/m E ook geelzucht (icterus), leverinsufficiëntie, acuut leverfalen, Guillain-Barré-syndroom, neuralgische amyotrofie, hepatocellulair carcinoom (HCC), polyarteritis nodosa en cirrose belicht.
Literatuur
go back to reference Busschots D, Ho E, Blach S, Razavi H, Van Damme B, Vanwelleghem T, et al. Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach. BMC Infect Dis. 2022;22;22(1):397. Busschots D, Ho E, Blach S, Razavi H, Van Damme B, Vanwelleghem T, et al. Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach. BMC Infect Dis. 2022;22;22(1):397.
go back to reference EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2020;73(5):1170–218. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2020;73(5):1170–218.
go back to reference EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256–71. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256–71.
go back to reference EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
go back to reference Fung S, Choi HS, Gehring A, Janssen HLA. Getting to HBV cure: the promising paths forward. Hepatology 2022;76(1);233–50.CrossRefPubMed Fung S, Choi HS, Gehring A, Janssen HLA. Getting to HBV cure: the promising paths forward. Hepatology 2022;76(1);233–50.CrossRefPubMed
go back to reference De Brier N, Koc ÖM, De Buck E, Muylaert A, Nevens F, Vanbrabant M. Hepatitis B virus prevalence in first-time blood donors in Flanders, Belgium: Impact of universal vaccination and migration. Transfusion. 2021;61(7):2125–36.CrossRefPubMed De Brier N, Koc ÖM, De Buck E, Muylaert A, Nevens F, Vanbrabant M. Hepatitis B virus prevalence in first-time blood donors in Flanders, Belgium: Impact of universal vaccination and migration. Transfusion. 2021;61(7):2125–36.CrossRefPubMed
go back to reference Koc ÖM, Kuypers D, Dupiont LJ, Vos R, Van Keer JM, Van Cleemput J. et al. The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidates. J Viral Hepat. 2021;28(1):105–11.CrossRefPubMed Koc ÖM, Kuypers D, Dupiont LJ, Vos R, Van Keer JM, Van Cleemput J. et al. The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidates. J Viral Hepat. 2021;28(1):105–11.CrossRefPubMed
go back to reference Koc ÖM, Robaeys G, Topal H, Bielen R, Busschots D, Fevery J, et al. Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long-term observational cohort study. J Med Virol. 2020;28;92(12):3373–80. Koc ÖM, Robaeys G, Topal H, Bielen R, Busschots D, Fevery J, et al. Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long-term observational cohort study. J Med Virol. 2020;28;92(12):3373–80.
go back to reference Koc Ö, Van Damme P, Busschots D, Bielen R, Forier A, Nevens F, et al. Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017. Euro Surveill. 2019;24(30):1900064.CrossRefPubMedPubMedCentral Koc Ö, Van Damme P, Busschots D, Bielen R, Forier A, Nevens F, et al. Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017. Euro Surveill. 2019;24(30):1900064.CrossRefPubMedPubMedCentral
go back to reference Peeters M, Schenk J, De Somer T, Roskams T, Locus T, Klamer S, et al. Viral clade is associated with severity of symptomatic genotype 3 Hepatitis E virus infections in Belgium, 2010-2018. J Hepatol. 2023;78(1):66–77.CrossRef Peeters M, Schenk J, De Somer T, Roskams T, Locus T, Klamer S, et al. Viral clade is associated with severity of symptomatic genotype 3 Hepatitis E virus infections in Belgium, 2010-2018. J Hepatol. 2023;78(1):66–77.CrossRef
go back to reference Poordad F, Felizarta F, Yao BB, Overcash JS, Hassanein T, Agarwal K, et al. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study. Liver Int. 2022;42(6):1278–86.CrossRefPubMed Poordad F, Felizarta F, Yao BB, Overcash JS, Hassanein T, Agarwal K, et al. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study. Liver Int. 2022;42(6):1278–86.CrossRefPubMed
go back to reference Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356(9):895–903.CrossRefPubMed Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356(9):895–903.CrossRefPubMed
go back to reference Vennema H, Bakker J, Veer B van der, Duizer E, Benne CA, et al. Swine-like hepatitis E virus are a cause of unexplained hepatitis in the Netherlands. J Viral Hepat. 2007;14:140–6.CrossRefPubMed Vennema H, Bakker J, Veer B van der, Duizer E, Benne CA, et al. Swine-like hepatitis E virus are a cause of unexplained hepatitis in the Netherlands. J Viral Hepat. 2007;14:140–6.CrossRefPubMed
go back to reference Verhoef L, Boot HJ, Koopmans M, Mollema L, Klis F van der, Reimerink J, Pelt W van. Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995-1996 and 2006-2007. Epidemiol Infect. 2011;139(8):1172–80.CrossRefPubMed Verhoef L, Boot HJ, Koopmans M, Mollema L, Klis F van der, Reimerink J, Pelt W van. Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995-1996 and 2006-2007. Epidemiol Infect. 2011;139(8):1172–80.CrossRefPubMed
Metagegevens
Titel
Infecties van de lever
Auteurs
A. A. van der Eijk
F. Nevens
R. A. de Man
Copyright
2024
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2944-1_17